A clinical trial to learn how an investigational drug (MP-101) affects on the laboratory signs of the disease when given to Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease (AD) patients
MP-101-02
Phase 1 other active
Quick answer
A clinical trial to learn how an investigational drug (MP-101) affects on the laboratory signs of the disease when given to Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease (AD) patients for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD) is a Phase 1 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD)
- Phase
- Phase 1
- Modality
- other
- Status
- active